nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—ABCB1—Lisinopril—systemic scleroderma	0.166	0.328	CbGbCtD
Scopolamine—ABCB1—Captopril—systemic scleroderma	0.125	0.246	CbGbCtD
Scopolamine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0981	0.193	CbGbCtD
Scopolamine—ABCB1—Prednisone—systemic scleroderma	0.0784	0.155	CbGbCtD
Scopolamine—ABCB1—Methotrexate—systemic scleroderma	0.0393	0.0776	CbGbCtD
Scopolamine—Sweating—Lisinopril—systemic scleroderma	0.00197	0.004	CcSEcCtD
Scopolamine—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00193	0.00392	CcSEcCtD
Scopolamine—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00193	0.00392	CcSEcCtD
Scopolamine—Arrhythmia—Leflunomide—systemic scleroderma	0.00192	0.00389	CcSEcCtD
Scopolamine—Eye disorder—Mycophenolic acid—systemic scleroderma	0.00191	0.00388	CcSEcCtD
Scopolamine—Dysuria—Mycophenolate mofetil—systemic scleroderma	0.00189	0.00383	CcSEcCtD
Scopolamine—Dry mouth—Captopril—systemic scleroderma	0.00189	0.00383	CcSEcCtD
Scopolamine—Mental disorder—Leflunomide—systemic scleroderma	0.00188	0.00382	CcSEcCtD
Scopolamine—Bradycardia—Lisinopril—systemic scleroderma	0.00188	0.00381	CcSEcCtD
Scopolamine—Confusional state—Captopril—systemic scleroderma	0.00187	0.00379	CcSEcCtD
Scopolamine—Hallucination—Lisinopril—systemic scleroderma	0.00184	0.00372	CcSEcCtD
Scopolamine—Pharyngitis—Lisinopril—systemic scleroderma	0.00183	0.00371	CcSEcCtD
Scopolamine—Arrhythmia—Mycophenolic acid—systemic scleroderma	0.00183	0.00371	CcSEcCtD
Scopolamine—Urinary tract disorder—Lisinopril—systemic scleroderma	0.00182	0.0037	CcSEcCtD
Scopolamine—Fatigue—Mometasone—systemic scleroderma	0.00182	0.00369	CcSEcCtD
Scopolamine—Urethral disorder—Lisinopril—systemic scleroderma	0.00181	0.00367	CcSEcCtD
Scopolamine—Tachycardia—Captopril—systemic scleroderma	0.00181	0.00366	CcSEcCtD
Scopolamine—Pain—Mometasone—systemic scleroderma	0.0018	0.00366	CcSEcCtD
Scopolamine—Mental disorder—Mycophenolic acid—systemic scleroderma	0.00179	0.00364	CcSEcCtD
Scopolamine—Vision blurred—Leflunomide—systemic scleroderma	0.00176	0.00357	CcSEcCtD
Scopolamine—Depressed level of consciousness—Methotrexate—systemic scleroderma	0.00176	0.00357	CcSEcCtD
Scopolamine—Asthenia—Pentoxifylline—systemic scleroderma	0.00175	0.00355	CcSEcCtD
Scopolamine—Conjunctivitis—Mycophenolate mofetil—systemic scleroderma	0.00175	0.00355	CcSEcCtD
Scopolamine—Hypotension—Captopril—systemic scleroderma	0.00173	0.00351	CcSEcCtD
Scopolamine—Pruritus—Pentoxifylline—systemic scleroderma	0.00173	0.0035	CcSEcCtD
Scopolamine—Sweating—Mycophenolate mofetil—systemic scleroderma	0.00173	0.0035	CcSEcCtD
Scopolamine—Flushing—Lisinopril—systemic scleroderma	0.00171	0.00347	CcSEcCtD
Scopolamine—Amnesia—Prednisone—systemic scleroderma	0.00169	0.00342	CcSEcCtD
Scopolamine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00168	0.00341	CcSEcCtD
Scopolamine—Vertigo—Leflunomide—systemic scleroderma	0.00168	0.00341	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00167	0.00339	CcSEcCtD
Scopolamine—Tremor—Mycophenolic acid—systemic scleroderma	0.00167	0.00339	CcSEcCtD
Scopolamine—Abdominal pain—Mometasone—systemic scleroderma	0.00167	0.00338	CcSEcCtD
Scopolamine—Body temperature increased—Mometasone—systemic scleroderma	0.00167	0.00338	CcSEcCtD
Scopolamine—Arrhythmia—Lisinopril—systemic scleroderma	0.00165	0.00334	CcSEcCtD
Scopolamine—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.00165	0.00334	CcSEcCtD
Scopolamine—Somnolence—Captopril—systemic scleroderma	0.00165	0.00334	CcSEcCtD
Scopolamine—Agitation—Mycophenolic acid—systemic scleroderma	0.00164	0.00332	CcSEcCtD
Scopolamine—Mental disorder—Lisinopril—systemic scleroderma	0.00162	0.00328	CcSEcCtD
Scopolamine—Dizziness—Pentoxifylline—systemic scleroderma	0.00162	0.00328	CcSEcCtD
Scopolamine—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.00161	0.00326	CcSEcCtD
Scopolamine—Erythema—Lisinopril—systemic scleroderma	0.00161	0.00326	CcSEcCtD
Scopolamine—Pharyngitis—Mycophenolate mofetil—systemic scleroderma	0.0016	0.00325	CcSEcCtD
Scopolamine—Vertigo—Mycophenolic acid—systemic scleroderma	0.0016	0.00325	CcSEcCtD
Scopolamine—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.0016	0.00324	CcSEcCtD
Scopolamine—Fatigue—Captopril—systemic scleroderma	0.0016	0.00324	CcSEcCtD
Scopolamine—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.00158	0.00321	CcSEcCtD
Scopolamine—Constipation—Captopril—systemic scleroderma	0.00158	0.00321	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00158	0.00321	CcSEcCtD
Scopolamine—Skin disorder—Azathioprine—systemic scleroderma	0.00157	0.00318	CcSEcCtD
Scopolamine—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.00156	0.00316	CcSEcCtD
Scopolamine—Dry mouth—Leflunomide—systemic scleroderma	0.00156	0.00316	CcSEcCtD
Scopolamine—Vomiting—Pentoxifylline—systemic scleroderma	0.00155	0.00315	CcSEcCtD
Scopolamine—Psychotic disorder—Prednisone—systemic scleroderma	0.00155	0.00314	CcSEcCtD
Scopolamine—Rash—Pentoxifylline—systemic scleroderma	0.00154	0.00312	CcSEcCtD
Scopolamine—Dermatitis—Pentoxifylline—systemic scleroderma	0.00154	0.00312	CcSEcCtD
Scopolamine—Headache—Pentoxifylline—systemic scleroderma	0.00153	0.0031	CcSEcCtD
Scopolamine—Feeling abnormal—Captopril—systemic scleroderma	0.00153	0.00309	CcSEcCtD
Scopolamine—Vision blurred—Lisinopril—systemic scleroderma	0.00151	0.00307	CcSEcCtD
Scopolamine—Asthenia—Mometasone—systemic scleroderma	0.00151	0.00307	CcSEcCtD
Scopolamine—Irritability—Prednisone—systemic scleroderma	0.00151	0.00307	CcSEcCtD
Scopolamine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.00151	0.00306	CcSEcCtD
Scopolamine—Hypotension—Azathioprine—systemic scleroderma	0.00151	0.00306	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00151	0.00306	CcSEcCtD
Scopolamine—Tremor—Lisinopril—systemic scleroderma	0.0015	0.00305	CcSEcCtD
Scopolamine—Nervous system disorder—Leflunomide—systemic scleroderma	0.0015	0.00303	CcSEcCtD
Scopolamine—Pruritus—Mometasone—systemic scleroderma	0.00149	0.00302	CcSEcCtD
Scopolamine—Tachycardia—Leflunomide—systemic scleroderma	0.00149	0.00302	CcSEcCtD
Scopolamine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00148	0.00301	CcSEcCtD
Scopolamine—Skin disorder—Leflunomide—systemic scleroderma	0.00148	0.00301	CcSEcCtD
Scopolamine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00147	0.00299	CcSEcCtD
Scopolamine—Confusional state—Mycophenolic acid—systemic scleroderma	0.00147	0.00298	CcSEcCtD
Scopolamine—Abdominal pain—Captopril—systemic scleroderma	0.00146	0.00297	CcSEcCtD
Scopolamine—Body temperature increased—Captopril—systemic scleroderma	0.00146	0.00297	CcSEcCtD
Scopolamine—Oedema—Mycophenolic acid—systemic scleroderma	0.00146	0.00295	CcSEcCtD
Scopolamine—Dry skin—Prednisone—systemic scleroderma	0.00145	0.00294	CcSEcCtD
Scopolamine—Nausea—Pentoxifylline—systemic scleroderma	0.00145	0.00294	CcSEcCtD
Scopolamine—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00293	CcSEcCtD
Scopolamine—Vertigo—Lisinopril—systemic scleroderma	0.00144	0.00293	CcSEcCtD
Scopolamine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00143	0.00289	CcSEcCtD
Scopolamine—Hypotension—Leflunomide—systemic scleroderma	0.00143	0.00289	CcSEcCtD
Scopolamine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00142	0.00288	CcSEcCtD
Scopolamine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00287	CcSEcCtD
Scopolamine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00141	0.00287	CcSEcCtD
Scopolamine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00141	0.00285	CcSEcCtD
Scopolamine—Muscular weakness—Prednisone—systemic scleroderma	0.0014	0.00283	CcSEcCtD
Scopolamine—Hypotension—Mycophenolic acid—systemic scleroderma	0.00136	0.00276	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00136	0.00275	CcSEcCtD
Scopolamine—Vomiting—Mometasone—systemic scleroderma	0.00134	0.00272	CcSEcCtD
Scopolamine—Dry mouth—Lisinopril—systemic scleroderma	0.00134	0.00271	CcSEcCtD
Scopolamine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00133	0.0027	CcSEcCtD
Scopolamine—Rash—Mometasone—systemic scleroderma	0.00133	0.0027	CcSEcCtD
Scopolamine—Asthenia—Captopril—systemic scleroderma	0.00133	0.00269	CcSEcCtD
Scopolamine—Dermatitis—Mometasone—systemic scleroderma	0.00133	0.00269	CcSEcCtD
Scopolamine—Confusional state—Lisinopril—systemic scleroderma	0.00132	0.00268	CcSEcCtD
Scopolamine—Headache—Mometasone—systemic scleroderma	0.00132	0.00268	CcSEcCtD
Scopolamine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00267	CcSEcCtD
Scopolamine—Fatigue—Leflunomide—systemic scleroderma	0.00132	0.00267	CcSEcCtD
Scopolamine—Oedema—Lisinopril—systemic scleroderma	0.00131	0.00266	CcSEcCtD
Scopolamine—Pruritus—Captopril—systemic scleroderma	0.00131	0.00266	CcSEcCtD
Scopolamine—Pain—Leflunomide—systemic scleroderma	0.0013	0.00265	CcSEcCtD
Scopolamine—Constipation—Leflunomide—systemic scleroderma	0.0013	0.00265	CcSEcCtD
Scopolamine—Somnolence—Mycophenolic acid—systemic scleroderma	0.00129	0.00262	CcSEcCtD
Scopolamine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00262	CcSEcCtD
Scopolamine—Tachycardia—Lisinopril—systemic scleroderma	0.00128	0.00259	CcSEcCtD
Scopolamine—Abdominal pain—Azathioprine—systemic scleroderma	0.00128	0.00259	CcSEcCtD
Scopolamine—Body temperature increased—Azathioprine—systemic scleroderma	0.00128	0.00259	CcSEcCtD
Scopolamine—Skin disorder—Lisinopril—systemic scleroderma	0.00127	0.00258	CcSEcCtD
Scopolamine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00127	0.00257	CcSEcCtD
Scopolamine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00256	CcSEcCtD
Scopolamine—Irritability—Methotrexate—systemic scleroderma	0.00126	0.00256	CcSEcCtD
Scopolamine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00126	0.00255	CcSEcCtD
Scopolamine—Fatigue—Mycophenolic acid—systemic scleroderma	0.00125	0.00254	CcSEcCtD
Scopolamine—Nausea—Mometasone—systemic scleroderma	0.00125	0.00254	CcSEcCtD
Scopolamine—Constipation—Mycophenolic acid—systemic scleroderma	0.00124	0.00252	CcSEcCtD
Scopolamine—Pain—Mycophenolic acid—systemic scleroderma	0.00124	0.00252	CcSEcCtD
Scopolamine—Hypotension—Lisinopril—systemic scleroderma	0.00122	0.00248	CcSEcCtD
Scopolamine—Dizziness—Captopril—systemic scleroderma	0.00122	0.00248	CcSEcCtD
Scopolamine—Body temperature increased—Leflunomide—systemic scleroderma	0.00121	0.00245	CcSEcCtD
Scopolamine—Abdominal pain—Leflunomide—systemic scleroderma	0.00121	0.00245	CcSEcCtD
Scopolamine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.0012	0.00243	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00241	CcSEcCtD
Scopolamine—Vomiting—Captopril—systemic scleroderma	0.00118	0.00239	CcSEcCtD
Scopolamine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00238	CcSEcCtD
Scopolamine—Rash—Captopril—systemic scleroderma	0.00117	0.00237	CcSEcCtD
Scopolamine—Dermatitis—Captopril—systemic scleroderma	0.00117	0.00237	CcSEcCtD
Scopolamine—Somnolence—Lisinopril—systemic scleroderma	0.00117	0.00236	CcSEcCtD
Scopolamine—Headache—Captopril—systemic scleroderma	0.00116	0.00235	CcSEcCtD
Scopolamine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00235	CcSEcCtD
Scopolamine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00115	0.00233	CcSEcCtD
Scopolamine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00115	0.00233	CcSEcCtD
Scopolamine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00233	CcSEcCtD
Scopolamine—Fatigue—Lisinopril—systemic scleroderma	0.00113	0.00229	CcSEcCtD
Scopolamine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00228	CcSEcCtD
Scopolamine—Pain—Lisinopril—systemic scleroderma	0.00112	0.00227	CcSEcCtD
Scopolamine—Constipation—Lisinopril—systemic scleroderma	0.00112	0.00227	CcSEcCtD
Scopolamine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00227	CcSEcCtD
Scopolamine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00226	CcSEcCtD
Scopolamine—Bradycardia—Prednisone—systemic scleroderma	0.00112	0.00226	CcSEcCtD
Scopolamine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00225	CcSEcCtD
Scopolamine—Nausea—Captopril—systemic scleroderma	0.0011	0.00223	CcSEcCtD
Scopolamine—Asthenia—Leflunomide—systemic scleroderma	0.00109	0.00222	CcSEcCtD
Scopolamine—Hallucination—Prednisone—systemic scleroderma	0.00109	0.00221	CcSEcCtD
Scopolamine—Feeling abnormal—Lisinopril—systemic scleroderma	0.00108	0.00219	CcSEcCtD
Scopolamine—Pruritus—Leflunomide—systemic scleroderma	0.00108	0.00219	CcSEcCtD
Scopolamine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00218	CcSEcCtD
Scopolamine—Dysuria—Methotrexate—systemic scleroderma	0.00107	0.00217	CcSEcCtD
Scopolamine—Dizziness—Azathioprine—systemic scleroderma	0.00107	0.00217	CcSEcCtD
Scopolamine—Asthenia—Mycophenolic acid—systemic scleroderma	0.00104	0.00212	CcSEcCtD
Scopolamine—Body temperature increased—Lisinopril—systemic scleroderma	0.00104	0.0021	CcSEcCtD
Scopolamine—Abdominal pain—Lisinopril—systemic scleroderma	0.00104	0.0021	CcSEcCtD
Scopolamine—Pruritus—Mycophenolic acid—systemic scleroderma	0.00103	0.00209	CcSEcCtD
Scopolamine—Vomiting—Azathioprine—systemic scleroderma	0.00103	0.00208	CcSEcCtD
Scopolamine—Eye disorder—Prednisone—systemic scleroderma	0.00102	0.00208	CcSEcCtD
Scopolamine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00207	CcSEcCtD
Scopolamine—Drowsiness—Methotrexate—systemic scleroderma	0.00102	0.00207	CcSEcCtD
Scopolamine—Rash—Azathioprine—systemic scleroderma	0.00102	0.00207	CcSEcCtD
Scopolamine—Dermatitis—Azathioprine—systemic scleroderma	0.00102	0.00206	CcSEcCtD
Scopolamine—Flushing—Prednisone—systemic scleroderma	0.00102	0.00206	CcSEcCtD
Scopolamine—Headache—Azathioprine—systemic scleroderma	0.00101	0.00205	CcSEcCtD
Scopolamine—Dizziness—Leflunomide—systemic scleroderma	0.00101	0.00205	CcSEcCtD
Scopolamine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000992	0.00201	CcSEcCtD
Scopolamine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000982	0.00199	CcSEcCtD
Scopolamine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000982	0.00199	CcSEcCtD
Scopolamine—Arrhythmia—Prednisone—systemic scleroderma	0.000979	0.00199	CcSEcCtD
Scopolamine—Sweating—Methotrexate—systemic scleroderma	0.000978	0.00198	CcSEcCtD
Scopolamine—Vomiting—Leflunomide—systemic scleroderma	0.00097	0.00197	CcSEcCtD
Scopolamine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000962	0.00195	CcSEcCtD
Scopolamine—Rash—Leflunomide—systemic scleroderma	0.000962	0.00195	CcSEcCtD
Scopolamine—Dermatitis—Leflunomide—systemic scleroderma	0.000961	0.00195	CcSEcCtD
Scopolamine—Mental disorder—Prednisone—systemic scleroderma	0.00096	0.00195	CcSEcCtD
Scopolamine—Nausea—Azathioprine—systemic scleroderma	0.00096	0.00195	CcSEcCtD
Scopolamine—Headache—Leflunomide—systemic scleroderma	0.000956	0.00194	CcSEcCtD
Scopolamine—Erythema—Prednisone—systemic scleroderma	0.000954	0.00193	CcSEcCtD
Scopolamine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000946	0.00192	CcSEcCtD
Scopolamine—Asthenia—Lisinopril—systemic scleroderma	0.00094	0.00191	CcSEcCtD
Scopolamine—Pruritus—Lisinopril—systemic scleroderma	0.000927	0.00188	CcSEcCtD
Scopolamine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000925	0.00188	CcSEcCtD
Scopolamine—Rash—Mycophenolic acid—systemic scleroderma	0.000918	0.00186	CcSEcCtD
Scopolamine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000917	0.00186	CcSEcCtD
Scopolamine—Headache—Mycophenolic acid—systemic scleroderma	0.000912	0.00185	CcSEcCtD
Scopolamine—Pharyngitis—Methotrexate—systemic scleroderma	0.000909	0.00184	CcSEcCtD
Scopolamine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000908	0.00184	CcSEcCtD
Scopolamine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000908	0.00184	CcSEcCtD
Scopolamine—Nausea—Leflunomide—systemic scleroderma	0.000906	0.00184	CcSEcCtD
Scopolamine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000904	0.00183	CcSEcCtD
Scopolamine—Vision blurred—Prednisone—systemic scleroderma	0.000899	0.00182	CcSEcCtD
Scopolamine—Urethral disorder—Methotrexate—systemic scleroderma	0.000898	0.00182	CcSEcCtD
Scopolamine—Visual impairment—Methotrexate—systemic scleroderma	0.000883	0.00179	CcSEcCtD
Scopolamine—Agitation—Prednisone—systemic scleroderma	0.000877	0.00178	CcSEcCtD
Scopolamine—Dizziness—Lisinopril—systemic scleroderma	0.000867	0.00176	CcSEcCtD
Scopolamine—Nausea—Mycophenolic acid—systemic scleroderma	0.000864	0.00175	CcSEcCtD
Scopolamine—Vertigo—Prednisone—systemic scleroderma	0.000857	0.00174	CcSEcCtD
Scopolamine—Eye disorder—Methotrexate—systemic scleroderma	0.000856	0.00174	CcSEcCtD
Scopolamine—Vomiting—Lisinopril—systemic scleroderma	0.000833	0.00169	CcSEcCtD
Scopolamine—Rash—Lisinopril—systemic scleroderma	0.000827	0.00168	CcSEcCtD
Scopolamine—Dermatitis—Lisinopril—systemic scleroderma	0.000826	0.00167	CcSEcCtD
Scopolamine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000824	0.00167	CcSEcCtD
Scopolamine—Headache—Lisinopril—systemic scleroderma	0.000821	0.00167	CcSEcCtD
Scopolamine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000813	0.00165	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000807	0.00164	CcSEcCtD
Scopolamine—Mental disorder—Methotrexate—systemic scleroderma	0.000802	0.00163	CcSEcCtD
Scopolamine—Erythema—Methotrexate—systemic scleroderma	0.000797	0.00162	CcSEcCtD
Scopolamine—Nausea—Lisinopril—systemic scleroderma	0.000779	0.00158	CcSEcCtD
Scopolamine—Oedema—Prednisone—systemic scleroderma	0.000779	0.00158	CcSEcCtD
Scopolamine—Nervous system disorder—Prednisone—systemic scleroderma	0.000763	0.00155	CcSEcCtD
Scopolamine—Tachycardia—Prednisone—systemic scleroderma	0.00076	0.00154	CcSEcCtD
Scopolamine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000759	0.00154	CcSEcCtD
Scopolamine—Skin disorder—Prednisone—systemic scleroderma	0.000756	0.00153	CcSEcCtD
Scopolamine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000753	0.00153	CcSEcCtD
Scopolamine—Vision blurred—Methotrexate—systemic scleroderma	0.000751	0.00152	CcSEcCtD
Scopolamine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00073	0.00148	CcSEcCtD
Scopolamine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000724	0.00147	CcSEcCtD
Scopolamine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000723	0.00147	CcSEcCtD
Scopolamine—Headache—Mycophenolate mofetil—systemic scleroderma	0.00072	0.00146	CcSEcCtD
Scopolamine—Vertigo—Methotrexate—systemic scleroderma	0.000716	0.00145	CcSEcCtD
Scopolamine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000682	0.00138	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000674	0.00137	CcSEcCtD
Scopolamine—Fatigue—Prednisone—systemic scleroderma	0.000671	0.00136	CcSEcCtD
Scopolamine—Constipation—Prednisone—systemic scleroderma	0.000666	0.00135	CcSEcCtD
Scopolamine—Confusional state—Methotrexate—systemic scleroderma	0.000656	0.00133	CcSEcCtD
Scopolamine—Feeling abnormal—Prednisone—systemic scleroderma	0.000642	0.0013	CcSEcCtD
Scopolamine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000638	0.00129	CcSEcCtD
Scopolamine—Skin disorder—Methotrexate—systemic scleroderma	0.000632	0.00128	CcSEcCtD
Scopolamine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000629	0.00128	CcSEcCtD
Scopolamine—Abdominal pain—Prednisone—systemic scleroderma	0.000615	0.00125	CcSEcCtD
Scopolamine—Body temperature increased—Prednisone—systemic scleroderma	0.000615	0.00125	CcSEcCtD
Scopolamine—Hypotension—Methotrexate—systemic scleroderma	0.000608	0.00123	CcSEcCtD
Scopolamine—Somnolence—Methotrexate—systemic scleroderma	0.000578	0.00117	CcSEcCtD
Scopolamine—Fatigue—Methotrexate—systemic scleroderma	0.000561	0.00114	CcSEcCtD
Scopolamine—Asthenia—Prednisone—systemic scleroderma	0.000559	0.00113	CcSEcCtD
Scopolamine—Pain—Methotrexate—systemic scleroderma	0.000556	0.00113	CcSEcCtD
Scopolamine—Pruritus—Prednisone—systemic scleroderma	0.000551	0.00112	CcSEcCtD
Scopolamine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000536	0.00109	CcSEcCtD
Scopolamine—Dizziness—Prednisone—systemic scleroderma	0.000515	0.00104	CcSEcCtD
Scopolamine—Abdominal pain—Methotrexate—systemic scleroderma	0.000514	0.00104	CcSEcCtD
Scopolamine—Body temperature increased—Methotrexate—systemic scleroderma	0.000514	0.00104	CcSEcCtD
Scopolamine—Vomiting—Prednisone—systemic scleroderma	0.000495	0.001	CcSEcCtD
Scopolamine—Rash—Prednisone—systemic scleroderma	0.000491	0.000996	CcSEcCtD
Scopolamine—Dermatitis—Prednisone—systemic scleroderma	0.00049	0.000995	CcSEcCtD
Scopolamine—Headache—Prednisone—systemic scleroderma	0.000488	0.000989	CcSEcCtD
Scopolamine—Asthenia—Methotrexate—systemic scleroderma	0.000467	0.000947	CcSEcCtD
Scopolamine—Nausea—Prednisone—systemic scleroderma	0.000462	0.000938	CcSEcCtD
Scopolamine—Pruritus—Methotrexate—systemic scleroderma	0.00046	0.000934	CcSEcCtD
Scopolamine—Dizziness—Methotrexate—systemic scleroderma	0.00043	0.000873	CcSEcCtD
Scopolamine—Vomiting—Methotrexate—systemic scleroderma	0.000414	0.000839	CcSEcCtD
Scopolamine—Rash—Methotrexate—systemic scleroderma	0.00041	0.000832	CcSEcCtD
Scopolamine—Dermatitis—Methotrexate—systemic scleroderma	0.00041	0.000831	CcSEcCtD
Scopolamine—Headache—Methotrexate—systemic scleroderma	0.000408	0.000827	CcSEcCtD
Scopolamine—Nausea—Methotrexate—systemic scleroderma	0.000386	0.000784	CcSEcCtD
